Founded in 1997, Ergomed plc is a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs. It operates globally in over 40 countries.

Ergomed plc has two complementary businesses:
(1) The Services Business – a well-established, clinical research business providing services to the pharmaceutical and biotechnology industry; and
(2) The Co-Development Business – a growing portfolio of partnerships with pharmaceutical and biotech companies, providing its drug development services in exchange for a carried interest in any revenues attributable to the drug asset, including outlicensing milestones as well as sales of the product

Since its formation, Ergomed plc has been providing expertise in clinical development / trial management from the largest pharmaceutical companies, as well as many small and mid-sized drug development companies. Ergomed plc successfully manages clinical development from Phase I through to late phase programmes.

Ergomed plc has a wide therapeutic focus, but has particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed plc believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed plc and the investigational sites involved in clinical trials. As well as providing high quality clinical development services, Ergomed plc is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed plc leverages its expertise and services in return for carried interest in the drugs under development.

The company has planned, managed, monitored, and reported clinical trials with a range of technologies that include small molecule drugs, monoclonal antibodies, tri-functional antibodies, soluble receptors and other targeted agents, cancer vaccines and immunotherapy, radioactive agents, and photodynamic therapies.

http://www.ergomedplc.com/

3 Jul N+1 Singer 290.00 Buy

Co-development partner news
RNS
RNS Number : 0252W
Ergomed plc
14 August 2015

Ergomed's Co-Development Partner Aeterna Zentaris Announces Data and Safety Monitoring Board Scheduled to Complete Second Interim Analysis of the ZoptEC Phase 3 Trial in Endometrial Cancer in Early October



Guildford, UK - 14 August 2015: Ergomed plc, (LSE: ERGO or 'Ergomed') a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, is pleased to note that its co-development partner Aeterna Zentaris (NASDAQ: AEZS) (TSX: AEZ), has announced that the Data and Safety Monitoring Board is scheduled to complete the second interim analysis of the Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) pivotal study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer in early October.



The announcement issued by Aeterna Zentaris follows:

Aeterna Zentaris Announces Data and Safety Monitoring Board Scheduled to Complete Second Interim Analysis of the ZoptEC Phase 3 Trial in Endometrial Cancer in Early October

Quebec City, Canada, August 11, 2015 - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the independent Data and Safety Monitoring Board ("DSMB") for the pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer, will complete a pre-specified second interim efficacy and safety analysis of the compound in early October 2015.

David Dodd, Chairman and CEO of Aeterna Zentaris, commented, "This past June 30, we announced that we had reached our goal of recruiting 500 patients for the Phase 3 ZoptEC study, marking the achievement of an important milestone in our efforts to commercialize this novel compound. Recently, we learned that the number of events required for the DSMB to conduct its second interim analysis had occurred. We are informed that the DSMB will conduct its review of the data in early October of this year, and we expect to be able to announce the results of the review soon thereafter. This review will be an important event in our development of zoptarelin doxorubicin. We are looking forward to learning the results of the DSMB's analysis."

Commenting on the compound, Dr. Richard Sachse, the Company's Chief Medical and Chief Scientific Officer, stated, "We believe that zoptarelin doxorubicin has the potential to become the first FDA approved medical therapy for advanced, recurrent endometrial cancer. This could result in its rapid adoption as a novel core therapy for treatment and management of advanced, recurrent endometrial cancer. Our hope is that the compound will improve and extend the quality of the lives of patients with this devastating disease."

About the ZoptEC Phase 3 trial

The ZoptEC Phase 3 trial is an open-label, randomized-controlled study, comparing the efficacy and safety of zoptarelin doxorubicin, a hybrid molecule composed of a synthetic peptide carrier and a well known chemotherapy agent, doxorubicin, to doxorubicin alone. The trial is fully recruited (over 500 patients) and is being conducted under a Special Protocol Assessment with the U.S. Food and Drug Administration ("FDA"). Patients are centrally randomized in a 1:1 ratio and receive either zoptarelin doxorubicin (267 mg/m2) or doxorubicin (60 mg/m2) intravenously, every 3 weeks and for up to 9 cycles. Response will be evaluated every 3 cycles during treatment, thereafter, every 12 weeks until progression. All patients will be followed for survival as the primary efficacy endpoint ("EP"). Secondary EPs include progression free survival, objective response-rate, and clinical benefit rate.



For more information on this trial, please consult (ClinicalTrials.gov Identifier: NCT01767155; EudraCT No: 2012-005546-38; ZoptEC: Zoptarelin doxorubicin in endometrial cancer).

ENDS

ergomed-eyeing-up-more-co-development-deals

Ergomed Interim Results 2015
RNS
RNS Number : 4986A
Ergomed plc
29 September 2015



Ergomed plc: Unaudited Interim results for the six months ended 30 June 2015



Strong first half trading performance - revenues up 85% and EBITDA up 66%

Strong backlog of signed contracts

Five co-development projects on track

New co-development deal signed with Dilaforette for orphan drug

Expansion into post-marketing service sector through Sound Opinion acquisition

Opened Asian office in Taipei



Guildford, UK - 29 September 2015: Ergomed plc, ('Ergomed', AIM: ERGO) a profitable UK-based company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces its interim results for the six months ended 30 June 2015.



KEY HIGHLIGHTS



Unaudited Financial Highlights



Ergomed plc



· H1 2015 revenues up 85% to £14.5 million from £7.8 million in H1 2014

· H1 2015 gross profit doubled to £4.2 million from £2.1 million in H1 2014

· *H1 2015 EBITDA up 66% to £1.5 million from £0.9 million in H1 2014

· H1 2015 adjusted EBITDA of £1.7 million excludes non-recurring costs of £0.2 million relating to M&A activities and the expense of establishing the new Taipei office

· Net assets of £15.9 million (H1 2014: £2.6 million; 31 December 2014: £15.3 million)

· Cash and cash equivalents of £4.9 million as of 30 June 2015 (H1 2014: £1.6 million; 31 December 2014: £4.6 million)

· Contribution in kind to co-development projects increased to £1.9 million in H1 2015 from £1.2 million in H1 2014



Unaudited Pro Forma** Financial Highlights



· **Pro forma revenues increased by 39% in H1 2015 to £14.5 million (H1 2014: £10.4 million)

· **Pro forma gross profit up 27% to £4.2 million in H1 2015 from £3.3 million in H1 2014



*EBITDA is earnings before tax, interest, depreciation, amortisation and share-based payment charge



**Pro forma numbers for H1 2014 are adjusted to include PrimeVigilance (PV), which was acquired in July 2014, in both periods and also adjusted for certain pre-IPO related party costs



Operational Highlights



· Contracts with a value of £15.0 million signed for clinical studies and pharmacovigilance projects in H1 2015 (£11.2 million signed in H1 2014) - strong backlog of awarded contracts of approximately £60 million at the end of August 2015, in line with expectations

· Medical Information business expanded in May 2015 through the acquisition of Sound Opinion Limited

· Signed first orphan disease co-development agreement with Dilaforette for Phase II clinical development of sevuparin in patients with sickle-cell disease (SCD)

· Three Phase III oncology co-development portfolio assets progressing as planned through on-going studies. Potential to receive over $100 million in future revenues if successful. Two of these Phase III reporting pivotal results in 2016 with Phase III interim analyses expected in Q4 2015

· One Phase II clinical study also due to report results in 2016

· Expanded presence in Asia with opening of office in Taiwan. This is in line with the Company's strategic growth plan set out at the IPO and the Taipei base will be used as a first step for expansion into Asia



Post-Period End Highlights



· Strengthened Board with the appointment of Andrew Mackie as Chief Business Officer

· Placing of 3.96 million founder shares at 170p per share in July 2015 with institutional shareholders in London and Europe and increasing free float to 37% from 27%





Commenting on the results, Miroslav Reljanovic M.D., Chief Executive Officer of Ergomed plc, said:

"Ergomed has delivered excellent results for the first half of 2015 and is well positioned for the rest of the year and into 2016. We have made very good progress delivering on some of our key strategic aims whilst achieving year-on-year growth.



"Our co-development portfolio is maturing and we are looking forward to our partners' late stage clinical data readouts in 2016. We continue to believe that significant value can be generated through focusing our drug development capability on co-development partnerships and as the portfolio expands, Ergomed will be in a position to place more emphasis on this element of the business. Certainly, we are seeing good opportunities in this sector and as one of the few companies taking a shared-risk approach, expect to be one of the leading beneficiaries of this trend going forward.



"The synergistic acquisition of Sound Opinion is in-line with our strategy to build our post-marketing services business, thereby generating strong recurring profits and a high value, focused business.



"Overall, we continue to believe that our hybrid model of a profitable, healthcare services business, combined with managed investment in an exciting co-development portfolio, has the potential to deliver significant value while balancing the risks over the next few years."



For further information, please contact:

Ergomed expands co-development with CEL-SCI
RNS
RNS Number : 2525B
Ergomed plc
05 October 2015



ERGOMED INCREASES ITS CO-DEVELOPMENT CONTRIBUTION IN CEL-SCI'S PHASE 3 HEAD AND NECK CANCER TRIAL



Guildford, UK - 5 October 2015: Ergomed plc, ('Ergomed', AIM: ERGO) a profitable UK-based company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs and CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company"), today announced that they have expanded their co-development agreement with increased activities to be undertaken by Ergomed. Pursuant to the expanded co-development agreement, Ergomed's contribution to the Phase 3 study will increase from $10 million to $12 million. The companies are undertaking the Phase 3 trial of CEL-SCI's investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary head and neck cancer.

Under the extended agreement, Ergomed will contribute up to $12 million towards the cost of performing clinical services for the Phase 3 study in exchange for a single digit percentage of milestone and royalty payments, up to a specified maximum amount. Well over 500 patients have been enrolled in the world's largest Phase 3 trial for head and neck cancer.

Miroslav Reljanovic M.D., Chief Executive Officer of Ergomed plc, said: "At this point in the clinical trial we have decided to increase our investment in the development of Multikine, as we believe that it holds the potential to treat head and neck cancer in a new way. Our potential returns from this agreement will increase in line with our investment."

CEL-SCI CEO Geert Kersten added: "Working with a skilled CRO, our Phase 3 trial is making significant progress towards completing study enrollment goals. We are pleased to enter into this expanded co-development agreement with Ergomed. It further aligns Ergomed's goals with CEL-SCI's as Ergomed will be rewarded for its $12,000,000 co-development investment from the commercialization of the drug."

Ergomed and Dilaforette Initiate Phase II
RNS
RNS Number : 0240C
Ergomed plc
13 October 2015



Ergomed and Dilaforette Initiate Phase II Clinical Trial with Dilaforette's Sevuparin in Sickle-Cell Disease



Guildford, UK and Stockholm, Sweden - 13 October 2015: Ergomed plc (AIM: ERGO), a profitable UK-based company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, and Dilaforette AB, a privately held Swedish drug development company focused on innovative treatments for patients with sickle-cell disease (SCD), today announced that the first patient has been enrolled in the Phase II study with sevuparin in patients with SCD.



The Phase II study is a multi-center, double-blind, placebo-controlled study in hospitalized SCD patients experiencing vaso-occlusive crisis (VOC). Both male and female SCD patients will be included and the target will be to have 70 evaluable patients. The patients are randomized and will be treated with i.v. infusion of sevuparin or placebo on top of standard pain medication, which is i.v. infusion of opioids given during the VOC. This Proof-of-Concept study is designed to demonstrate reduced time to resolution of VOC, defined as freedom from parenteral opioid use and readiness for discharge from hospital. Secondary end-points include pharmacokinetics and safety. The study is planned to be performed in four countries in Europe and Middle East. The study is performed under a co-development deal with Ergomed, where Ergomed will co-invest a proportion of its revenues from the clinical and regulatory activities of this trial in return for an equity stake in Dilaforette.



Dilaforette's sevuparin is an innovative, proprietary polysaccharide drug which has the potential to restore blood flow and prevent further microvascular obstructions caused by abnormal blood cells in SCD patients. With its anti-adhesive properties, sevuparin could offer treatment of the underlying cause of VOC in SCD patients, potentially facilitating earlier pain relief, shorter hospital stays, reduced need of opioids and improved quality of life. Resolving the microvascular obstructions with sevuparin may also affect long term outcomes by avoiding additional tissue and organ damage thereby reducing co-morbidities and possibly also mortality.



Dr Miroslav Reljanovic, CEO of Ergomed, commented, "As our first co-development agreement in orphan drug development, we are very pleased to see the first patient recruited into the trial. The start of the study is an exciting milestone for Ergomed and our collaboration with Dilaforette reaffirms our commitment to developing drugs for rare diseases."



"We are excited about having initiated this Proof-of-Concept trial for sevuparin and are looking forward to the study results which are expected in the second half of 2016. With sevuparin, Dilaforette aims to introduce an innovative, new treatment option for SCD patients, for the first time addressing the cause and not just the symptoms of vaso-occlusion," said Christina Herder, CEO of Dilaforette.



"SCD is a disease with a large, unmet medical need where current treatment focuses on the symptomatic relief of pain rather than treating the underlying cause of VOCs, namely the sickle cell related obstructions of the microvasculature. SCD is associated with a number of acute health problems including VOC, where sevuparin has the potential to significantly improve quality of life for these patients", said Dr Bart Biemond, Academic Medical Centre, Amsterdam, the Netherlands, Principal Investigator in the study.



SCD is a disabling and potentially fatal disease with a large unmet medical need in both the developed and developing world. In the US and in Europe, it is estimated that close to 100,000 and 35,000 patients, respectively, are diagnosed with this hereditary disease. There is also an even larger patient pool in the Middle East and North Africa (MENA) region. SCD patients undergo on average one VOC per year. This acute complication is caused by sickle blood cells obstructing the blood flow to vital organs leading to ischemia and often severe pain. Long-term, SCD patients are at risk of organ damage and premature death.

ENDS

Who Should Attend?Date:

Thursday 30th June 2016

Venue:

Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR

Event Timings:Sponsored by:

Half-year Report
RNS
RNS Number : 7528K
Ergomed plc
26 September 2016
 
PRESS RELEASE
 
Unaudited Interim results for the six months ended 30 June 2016
 
Strong first half financial performance - revenues up 21% and gross profit up 26%
£19 million new contracts signed resulting in a backlog of £60 million
Acquisitions of O+P and GASD strengthens service business
Acquisition of Haemostatix expands product pipeline potential significantly
Completion of £9.2 million fund raising
 
 
Guildford, UK - 26 September 2016: Ergomed plc, ('Ergomed', 'the Company', AIM: ERGO) a profitable UK-based company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces its interim results for the six months ended 30 June 2016.
 
Commenting on the results, Miroslav Reljanovic M.D., Chief Executive Officer of Ergomed plc, said:
"Ergomed has delivered another set of excellent results for the first half of 2016. We made significant progress against our strategic goals through the continued strong trading performance of our profitable, growing service businesses where overall top-line growth of 21% was driven by revenue growth of 53% in our subsidiary company PrimeVigilance and through the completion of two targeted acquisitions.
 
The acquisitions of O+P and GASD augment the continuing growth of our services businesses, adding immediate significant, tangible value including an in-house Electronic Data Capture system, "OPVERDI" and biostatistics and data management capabilities. We have already won our first service contract together for a clinical study with a European biotech company underlining the benefits of the acquisition.
 
We continue to believe we can create significant value by investing in-kind through carefully selected co-development partnerships and we are expecting important clinical data readouts from Ferrer and Aeterna Zentaris around the end of 2016 and early 2017 respectively. The Haemostatix acquisition is an exciting evolution of the co-development model and has the potential to be transformational for Ergomed through the rapid development of its novel treatment for surgical bleeding.
 
Overall, we continue to believe that our hybrid model of a growing, profitable services business combined with managed risk drug development has the potential to deliver significant shareholder value over the next few years with some exciting newsflow in the next 12 months."
 
 
Financial highlights (unaudited)
 
·      Revenues up 21% to £17.6 million from £14.5 million in H1 2015
o  Including revenue growth of 53% to £5.5 million from £3.6 million in H1 2015 from PrimeVigilance
·      Gross profit up 26% to £5.3 million from £4.2 million in H1 2015
·      Adjusted EBITDA up 12% to £1.9 million from £1.7 million in H1 2015 excludes costs of £0.4 million relating to M&A activities and £0.1 million of R&D costs (note 11)
·      EBITDA before adjustments for share-based payment charge, M&A costs, exceptional items and R&D of £1.2 million compared with £1.4 million in H1 2015 (note 11)
·      Placing of 6.63 million new ordinary shares raised £9.2 million before expenses
·      Cash and cash equivalents of £9.9 million as of 30 June 2016 (30 June 2015: £4.9 million; 31 December 2015: £4.0 million)
·      Contribution in kind to co-development projects increased to £2.1 million in H1 2016 from £1.9 million in H1 2015
 
 
Operational highlights
 
·      Service contracts with a value of £19 million signed in H1 2016 (£15 million signed in H1 2015)
·      Strong backlog of awarded contracts of approximately £60 million at the end of July 2016
·      O+P and GASD, a contract research organisation with a proprietary electronic data capture system, OPVERDI, and a biostatistics and data management company respectively, were acquired on 13 June 2016 (note 8)
·      Opening of a new office in Boston, MA to support growth of PrimeVigilance in the US in June 2016
·      Five ongoing clinical studies with co-development partnerships proceeding to plan
·      Haemostatix, a UK company developing a proprietary platform to control surgical bleeding with two lead products, one of which is Phase IIb ready, was acquired on 24 May 2016 (note 7)

26 Sep
N+1 Singer
N/A
Buy

22 Sep
Stifel
271.00
Buy

2 Sep
Stifel
271.00
Buy

15:30 04/04/2017
Director Deals - Ergomed Plc (ERGO)
Peter George, Non Executive Director, bought 100,000 shares in the company on the 3rd April 2017 at a price of 190.00p. The Director now holds 100,000 shares. Story provided by StockMarketWire.com Director deals data provided by www.directorsholdings.com

4 Apr
Numis
300.00
Buy
4 Apr
Stifel
315.00
Buy

RNS
RNS Number : 2686U
Ergomed plc
23 October 2017
 
PRESS RELEASE
 
 
Ergomed's first-in-class haemostat, PeproStat™, reports positive top-line results and meets key endpoints in Phase II study
 
-     Highly innovative blood free haemostat met the primary efficacy endpoint of superiority over standard of care in time to haemostasis with statistical significance across all surgery types tested
 
-     PeproStat was seen to be safe with no treatment related SAEs reported and no re-bleeding
 
-     PeproStat™ demonstrated superiority in time to haemostasis at each time point during 10-minutes assessment over standard of care
 
-     PeproStat had a higher response rate, with more investigators finding the product good to excellent with respect to control of bleeding compared to standard of care and the "liquid and sponge" format easy/very easy to use
 
-     Results reinforce potential as a safe, blood-free, ready-to-use and cost-effective method of controlling bleeding during surgery
 
-     Phase II results ahead of original schedule; preparation for Phase III in 2018 and potential entry to $2.5 billion global market1
 
 
London, UK - 23 October 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a specialised pharmaceutical services and drug development company, today announces positive top-line results from its Phase II clinical trial of PeproStat™, the Company's potential first-in-class coagulant, or 'haemostat', for intraoperative surgical bleeding. PeproStat is a novel, blood-free, ready-to-use, cost-effective, product based on a peptide which binds fibrinogen.
 
The Phase II clinical trial was carried out at 16 hospitals across five European countries and treated 169 patients undergoing three types of surgical procedure: liver/soft tissue; vascular and spinal. The trial was double blinded and compared PeproStat to standard of care (gelatin sponge). In the control arm, patient bleeds were treated by applying pressure with a gelatin sponge soaked in saline, which represents standard of care in Europe. In the treatment arm, the sponge was soaked with PeproStat. The safety profile of the product was good, with no treatment-related serious adverse events, and no re-bleeding after the observation period.
 
PeproStat reduced the time to haemostasis (TTH) by 1.55 minutes (p <0.0041) across all surgery types, demonstrating superiority compared to the standard of care, the primary efficacy endpoint of the trial, a statistically and clinically significant result and one which compares favourably with literature on comparative products. Notably, in 58.2% of patients the TTH was equal or less than 2 minutes (standard of care: 32.7%).
 
The absolute TTH of both PeproStat and standard of care were higher (4.2 minutes and 5.8 minutes respectively) than seen in the Phase I trial which may be due to the observation that there was a greater proportion of moderate (vs mild) levels of bleeding in this trial compared with the Phase I trial and seen in trials of competitor products.
 
80.9% of investigators in the trial rated the product as good to excellent, compared to 59.6% for standard of care with respect to controlling bleeding. In addition to improved efficacy, 93.5% of investigators rated the liquid plus sponge format as easy to very easy to use, confirming the product's design as a ready to use formulation.
 
Ergomed plans to submit detailed data, once a full analysis is complete, for presentation at upcoming scientific conferences.
 
Dr Dan Weng, Chief Executive Officer of Ergomed, said: ""We are delighted to report positive results from the Phase II study. We believe PeproStat is a first-in-class product which could enter the large and growing haemostat market as early as 2020. We have already completed our first commercial agreement for PeproStat and our other haemostat, ReadyFlow, with Boryung in September, and will now explore our options to bring this first-in-class haemostat to the market as soon as possible. Currently, we have a number of active licensing and partnering discussions to fund further development."
 
Dr Paul Hayes, Addenbrookes Hospital, Cambridge, UK, the Chief Investigator for the trial, said: "Surgical bleeding is a common problem that can be associated with significant blood loss, increasing patient morbidity and mortality. PeproStat works fast and has shown to reduce the non-responder rate by almost 50% compared to a current standard of care product. This provides surgeons with a huge and clinically relevant advantage in providing better control of excess bleeding during surgery and could be hugely beneficial to patients, reducing operation times, complications and preventing unnecessary returns to surgery. I am both impressed by Ergomed's ability to bring this innovative product through Phase II so efficiently, and really excited by the results we have seen, demonstrating the potential of PeproStat as an important new alternative."
 
The global haemostat market is estimated to be worth $2.5 billion1. Current products may be limited by a range of issues, including slow onset of action and long preparation time. PeproStat, based on a synthetic peptide which eliminates the risk of exposure to blood derived materials, is more stable allowing the formulation of ready-to-use preparations and has a fast mode of action. With these advantages, Ergomed expects the product will gain significant market share.
 
PeproStat is the lead product in Ergomed's Haemostatix portfolio, with ReadyFlowTM in mid-stage pre-clinical development. Ergomed believes that together these two products are estimated to have peak sales potential of more than $500 million2.
 
The Phase II study completed six months ahead of the original schedule, demonstrating both strong physician interest in this innovative haemostat, and Ergomed's ability as a specialist drug developer to efficiently recruit patients fit for study purpose.
 
Ergomed will hold a conference call for analysts at 08:30 BST. Dial-in details are: +44 (0) 1452 555 566. Conference ID: 9677908#. For a copy of the presentation, please email ergomed@consilium-comms.com.
 
1 Hemostats Market by Product Type (Thrombin, Oxidised Regenerated Cellulose, Combination, Gelatin, Collagen), and Geography (Americas, Europe, APAC, MEA) - Global Forecast to 2020. MarketsandMarkets, February 2016.
2 Company estimate
 
ENDS
 

12:20 23/10/2017
Broker Forecast - Numis issues a broker note on Ergomed Plc
Numis today reaffirms its buy investment rating on Ergomed Plc (LON:ERGO) and raised its price target to 300p (from 280p). Story provided by StockMarketWire.com